Eurofins Scientific's stock fell by 4.16% on Thursday, closing at €67.68 down from €70.62 the previous day. This decline occurred on the same day the company announced solid preliminary results for 2025, featuring a 24% increase in earnings per share to €2.31 and an organic growth of 4.1%. Concurrently, the group increased its dividend by 20% to €0.72 per share.
Eurofins Scientific has shown a substantial improvement in profitability for the past fiscal year. Earnings per share increased by 24% to €2.31, reflecting a favorable operational momentum. The organic growth of 4.1% indicates a sustained expansion of the group's activities in a measured market environment. In terms of shareholder distribution, the group has strengthened its dividend policy by increasing it by 20%, raising it to €0.72 per share, signaling increased confidence in its cash flow generation trajectory.
Divergent Analyst Recommendations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Analyst recommendations vary on the medium-term outlook. Kepler Cheuvreux has raised its price target from €72.00 to €81.00, implying an upside potential of 19.6% from the current price. Meanwhile, Morgan Stanley maintains its 'market weight' stance while modestly raising its target from €61.00 to €64.00, representing a limited potential of 5.5%. This divergence in opinion between the two firms reflects nuanced views on the valuation of the stock following the announcement of its annual results.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
